A recent phase II trial in bile duct cancer with cabozantinib, a multi-kinase inhibitor targeting VEGFR2, MET and AXL, supports targeting receptor tyrosine kinases such as AXL as possible therapeutic targets to treat cholangiocarcinoma [10]. This evidence concerns the gene AXL and cholangiocarcinoma.